PDCD1 and neoplasm: Metformin, a commonly utilized type II diabetes drug, has been shown to metabolically reprogram the tumor microenvironment (TME) (7), and in pre-clinical models, to augment the effectiveness of anti-programmed cell death protein 1 (PD1) IMT (8).